REGULATED PRESS RELEASE published on 03/08/2024 at 07:00, 7 months 11 days ago Biophytis a présenté le potentiel de RuvembriTM dans le traitement de la dystrophie musculaire de Duchenne Biophytis présente les résultats prometteurs de RuvembriTM dans le traitement de la dystrophie musculaire de Duchenne lors de la MDA Clinical & Scientific Conference. Objectif : essai clinique de phase 1-2 en 2024 Biophytis Essai Clinique RuvembriTM Dystrophie Musculaire De Duchenne MDA Clinical & Scientific Conference
REGULATED PRESS RELEASE published on 03/08/2024 at 07:00, 7 months 11 days ago Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy Biophytis presents RuvembriTM potential in Duchenne Muscular Dystrophy treatment at MDA Conference, showing efficacy in clinical trials. CEO highlights medical need and market value increase Biophytis Clinical Trials RuvembriTM Duchenne Muscular Dystrophy Market Value
ARTICLE published on 01/04/2024 at 07:35, 9 months 15 days ago Biophytis dévoile l'étude COVA prometteuse contre la COVID-19 Biophytis publie des résultats encourageants de l'étude COVA sur son traitement Sarconeos (BIO101) contre les formes sévères de COVID-19 Biophytis COVID-19 EClinicalMedicine Sarconeos (BIO101) COVA
PRESS RELEASE published on 01/04/2024 at 07:00, 9 months 15 days ago Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA dans eClinicalMedicine, partie de The Lancet Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA dans eClinicalMedicine, partie de The Lancet. Biophytis, société de biotechnologie, annonce des résultats prometteurs pour le traitement des symptômes respiratoires des formes sévères de COVID-19 Biophytis COVID-19 EClinicalMedicine Étude De Phase 2-3 COVA Société De Biotechnologie
PRESS RELEASE published on 01/04/2024 at 07:00, 9 months 15 days ago Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet. The publication highlights the positive results of Sarconeos (BIO101) in reducing the risk of death or respiratory failure in adults hospitalized with severe respiratory symptoms due to COVID-19. Biophytis will also host press conferences to discuss the potential and clinical benefits of Sarconeos (BIO101) in severe forms of COVID-19 and its exploration in the treatment of other respiratory viral infections. For more information, visit www.biophytis.com Biophytis COVA Phase 2-3 Study Sarconeos (BIO101) Publication Severe COVID-19 Treatment Respiratory Viral Infections Clinical Benefits Of Sarconeos (BIO101)
ARTICLE published on 12/29/2023 at 07:59, 9 months 21 days ago Biophytis avance dans son financement avec l'émission de la quatrième tranche d'ORNANE Biophytis annonce le tirage de la quatrième tranche d'ORNANE auprès du fonds d’investissement Atlas sous le cadre du contrat de financement conclu en 2021 Biophytis Financement ORNANE Atlas Médicament
PRESS RELEASE published on 12/29/2023 at 07:00, 9 months 21 days ago Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021 Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du contrat Atlas 2021. La société de biotechnologie au stade clinique spécialisée dans le développement de traitements qui visent à ralentir les processus dégénératifs liés au vieillissement va émettre 80 ORNANE pour un montant de 2 millions d’euros, avec une option complémentaire de 80 ORNANE pour un montant de 2 millions d’euros le 15 février 2024 Biophytis ORNANE Atlas 2021 Fonds D'investissement Obligations Remboursables
PRESS RELEASE published on 12/29/2023 at 07:00, 9 months 21 days ago Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Biophytis, a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases, has announced the drawing of the fourth tranche of its convertible bond agreement with Atlas, a specialized investment fund based in New York. This tranche consists of 80 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with a total value of €4 million. The ORNANE have a 24-month maturity period and do not bear interest. Holders have the option
ARTICLE published on 12/11/2023 at 07:49, 10 months 8 days ago Biophytis présente son calendrier de conférences internationales pour le premier trimestre 2024 Biophytis SA confirme sa présence dans des conférences clés du secteur de la santé, visant à renforcer ses relations et à présenter ses avancées Biophytis Biotechnologie Sarconeos (BIO101) Conférences Traitements Anti-vieillissement
ARTICLE published on 12/04/2023 at 08:00, 10 months 15 days ago Biophytis et l'Université de Liège s'associent pour combattre l'insuffisance respiratoire virale Biophytis annonce un partenariat avec l'Université de Liège pour étudier Sarconeos (BIO101) dans le traitement de pathologies respiratoires Biophytis Université De Liège Insuffisance Respiratoire Recherche Préclinique Médicament Sarconeos
Published on 10/19/2024 at 00:20, 11 hours 23 minutes ago Bermuda Carbon Commission Debuts at Green Overseas Climate Finance Forum: Setting a Global Standard for Blue Carbon Innovation
Published on 10/18/2024 at 20:00, 15 hours 43 minutes ago Western Alaska Minerals Announces Grant of Restricted Share Units
Published on 10/18/2024 at 15:00, 20 hours 43 minutes ago Namibia Critical Metals Receives Environmental Clearance Certificate for Mining Activities on its Lofdal Heavy Rare Earth Project
Published on 10/18/2024 at 14:31, 21 hours 12 minutes ago Vicinity Motor Corp. Receives Notice from RBC of Intent to File Receivership Order on Monday, October 21, 2024
Published on 10/18/2024 at 14:00, 21 hours 43 minutes ago Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions
Published on 10/19/2024 at 05:59, 5 hours 43 minutes ago Policy Address by Hong Kong SAR’s Chief Executive John Lee: Improving People’s Livelihood in Pursuit of Happiness
Published on 10/18/2024 at 22:18, 13 hours 24 minutes ago Investor Materials Ahead of Trading Resumption
Published on 10/18/2024 at 22:14, 13 hours 28 minutes ago EQS-Adhoc: aap Implantate AG: Step-by-step restart of IT systems
Published on 10/18/2024 at 19:45, 15 hours 58 minutes ago Springer Nature - Exercise & Post-Stabilisation
Published on 10/18/2024 at 18:30, 17 hours 13 minutes ago For the track and the road: The new 911 GT3 and 911 GT3 with Touring package
Published on 10/18/2024 at 18:55, 16 hours 47 minutes ago LDC : Accord en vue de l’acquisition de European Convenience Food (ECF) en Allemagne.
Published on 10/18/2024 at 18:55, 16 hours 47 minutes ago LDC : Entry into an agreement for the acquisition of European Convenience Food (ECF) in Germany.
Published on 10/18/2024 at 17:45, 17 hours 58 minutes ago TINC investeert in de veilige en vlotte doorstroming van de ringweg rond Brussel (B)
Published on 10/18/2024 at 17:45, 17 hours 58 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)
Published on 10/18/2024 at 17:45, 17 hours 58 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)